Skip Navigation

Cardiovascular Research 2006 72(1):51-59; doi:10.1016/j.cardiores.2006.06.026
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Burger, D.
Right arrow Articles by Feng, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burger, D.
Right arrow Articles by Feng, Q.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase

Dylan Burgera,c, Ming Leia,b, Nicola Geoghegan-Morpheta,c, Xiangru Lua, Anargyros Xenocostasd and Qingping Fenga,b,c,*

aCardiology Research Laboratory, Centre for Critical Illness Research, Lawson Health Research Institute, London, Ontario, Canada
bDepartment of Medicine, University of Western Ontario, London, Ontario, Canada
cDepartment of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada
dDepartment of Medicine, Division of Hematology, University of Western Ontario, London, Ontario, Canada

* Corresponding author. Cardiology Research Laboratory, Lawson Health Research Institute, VRL 6th Floor, A6-134, 800 Commissioners Road, London, Ontario, Canada N6A 4G5. Tel.: +1 519 685 8300x55443; fax: +1 519 685 8341. Email address: qfeng{at}uwo.ca

Objective: Erythropoietin (EPO), a cytokine best known for its ability to increase red blood cell mass, has recently been shown to protect cardiomyocytes from apoptotic cell death. The objective of the present study was to investigate the role of endothelial nitric oxide synthase (eNOS) in the anti-apoptotic effects of EPO in cardiomyocytes.

Methods and results: Neonatal mouse ventricular cardiomyocytes were isolated and cultured from wild-type and eNOS–/– mice. Treatment with EPO significantly reduced apoptosis induced by norepinephrine (NE) in the wild-type cardiomyocytes. The reduction of apoptosis was associated with significant increases in eNOS expression, phosphorylation and NO production. However, the anti-apoptotic effects of EPO were significantly decreased in wild-type cardiomyocytes treated with L-NAME, which inhibits nitric oxide synthase activity. The results were further confirmed using eNOS–/– cardiomyocytes. To investigate the in vivo significance of eNOS in mediating the anti-apoptotic effects of EPO, wild-type and eNOS–/– mice were subjected to myocardial ischemia and reperfusion. EPO decreased myocardial apoptosis and infarct size in wild-type mice. However, the protective effects of EPO were significantly diminished in eNOS–/– mice.

Conclusions: EPO increases eNOS expression and NO production in cardiomyocytes. The anti-apoptotic effects of EPO in cardiomyocytes are mediated by eNOS-derived NO production.

KEYWORDS Apoptosis; Myocytes; Ischemia; Nitric oxide; Nitric oxide synthase; Signal transduction; Erythropoietin

Time for primary review 27 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. E. Burger, F.-L. Xiang, L. Hammoud, D. L. Jones, and Q. Feng
Erythropoietin Protects the Heart from Ventricular Arrhythmia during Ischemia and Reperfusion via Neuronal Nitric-Oxide Synthase
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 900 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
D. Mihov, N. Bogdanov, B. Grenacher, M. Gassmann, G. Zund, A. Bogdanova, and R. Tavakoli
Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production
Eur. J. Cardiothorac. Surg., May 1, 2009; 35(5): 839 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
N. Li, X. Lu, X. Zhao, F.-L. Xiang, A. Xenocostas, M. Karmazyn, and Q. Feng
Endothelial Nitric Oxide Synthase Promotes Bone Marrow Stromal Cell Migration to the Ischemic Myocardium via Upregulation of Stromal Cell-Derived Factor-1{alpha}
Stem Cells, April 1, 2009; 27(4): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
L. Hammoud, D. E. Burger, X. Lu, and Q. Feng
Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling
Am J Physiol Cell Physiol, April 1, 2009; 296(4): C735 - C745.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Burger, F. Xiang, L. Hammoud, X. Lu, and Q. Feng
Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion
Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H84 - H93.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. R. Ward and D. J. Stewart
Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three?
Cardiovasc Res, August 1, 2008; 79(3): 357 - 359.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.